Aquestive Therapeutics (AQST) Return on Invested Capital (2023 - 2025)

Aquestive Therapeutics' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 4.12% for Q1 2025.

• On a quarterly basis, Return on Invested Capital fell 411.0% year-over-year to 4.12% in Q1 2025; TTM through Mar 2025 was 4.12%, a 411.0% decrease from a year earlier, with the FY2024 full-year figure at 12.82%, down 1280.0% from the prior year.
• Return on Invested Capital declined to 4.12% in Q1 2025 per AQST's latest filing, from 3.2% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.0% in Q4 2023 and bottomed at 4.12% in Q1 2025.
• The 3-year median for Return on Invested Capital is 0.01% (2024), against an average of 0.93%.
• Across the five-year window, Return on Invested Capital declined 1 bps in 2024 and plunged 411 bps in 2025, its largest moves.
• Year by year, Return on Invested Capital stood at 0.0% in 2023, then slumped by 101707 bps to 3.2% in 2024, then dropped by 28 bps to 4.12% in 2025.
• Per Business Quant, the three latest AQST Return on Invested Capital figures stand at 4.12% (Q1 2025), 3.2% (Q4 2024), and 0.09% (Q3 2024).